Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Quick Summary

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Feb 24, 2022 5:24pm

124 Views

Post# 34459761

RE:RE:Quick Summary

TH1902 conjugates two docetaxel molecules as per preclinical results a quarter of the PDC would equal same concentration of docetaxel alone once internalized doing the math you end up
with 10 or more intra cellular concentration.

JayjayUSA12007 wrote: Thanks for the summary:
How do you come up with this statement:"It seems the MTD will be at 300mg/m2 which is about 10 times more intracellular concentration of the docetaxel alone" ?

As 300 mg/m2 is about 1.5x the normal docetaxel treatment standard of care, if use this dose results in 10 times more intracellular concentration then SORT+ technology was proven. Is it your understanding as well ?